# A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

> **NCT05500222** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Madrigal Pharmaceuticals, Inc.** · enrollment: 700 (estimated)

## Conditions studied

- NASH
- Cirrhosis, Liver

## Interventions

- **DRUG:** Resmetirom
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05500222
- **Lead sponsor:** Madrigal Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-26
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05500222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05500222, "A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05500222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*